Adjuvant Zoledronic Acid in High‐Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial

LESSONS LEARNED. Adjuvant treatment with zoledronic acid did not decrease the recurrence rate of giant cell tumor of bone (GCTB) in this study. The efficacy could not be determined because of the small sample size. GCTB recurrences, even in the denosumab era, are still an issue; therefore, a randomi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Lipplaa, Astrid, Kroep, Judith R., van der Heijden, Lizz, Jutte, Paul C., Hogendoorn, Pancras C.W., Dijkstra, Sander, Gelderblom, Hans
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656477/
https://ncbi.nlm.nih.gov/pubmed/31040253
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0280
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados